Mary Clare Kennedy1,2, Mohammad Karamouzian1,3, Thomas Kerr4,5. 1. British Columbia Centre on Substance Use, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. 2. School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC, V6T 1Z3, Canada. 3. HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. 4. British Columbia Centre on Substance Use, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. uhri-tk@cfenet.ubc.ca. 5. Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. uhri-tk@cfenet.ubc.ca.
Abstract
PURPOSE OF REVIEW: Supervised drug consumption facilities (SCFs) have increasingly been implemented in response to public health and public order concerns associated with illicit drug use. We systematically reviewed the literature investigating the health and community impacts of SCFs. RECENT FINDINGS: Consistent evidence demonstrates that SCFs mitigate overdose-related harms and unsafe drug use behaviours, as well as facilitate uptake of addiction treatment and other health services among people who use drugs (PWUD). Further, SCFs have been associated with improvements in public order without increasing drug-related crime. SCFs have also been shown to be cost-effective. This systematic review suggests that SCFs are effectively meeting their primary public health and order objectives and therefore supports their role within a continuum of services for PWUD. Additional studies are needed to better understand the potential long-term health impacts of SCFs and how innovations in SCF programming may help to optimize the effectiveness of this intervention.
PURPOSE OF REVIEW: Supervised drug consumption facilities (SCFs) have increasingly been implemented in response to public health and public order concerns associated with illicit drug use. We systematically reviewed the literature investigating the health and community impacts of SCFs. RECENT FINDINGS: Consistent evidence demonstrates that SCFs mitigate overdose-related harms and unsafe drug use behaviours, as well as facilitate uptake of addiction treatment and other health services among people who use drugs (PWUD). Further, SCFs have been associated with improvements in public order without increasing drug-related crime. SCFs have also been shown to be cost-effective. This systematic review suggests that SCFs are effectively meeting their primary public health and order objectives and therefore supports their role within a continuum of services for PWUD. Additional studies are needed to better understand the potential long-term health impacts of SCFs and how innovations in SCF programming may help to optimize the effectiveness of this intervention.
Entities:
Keywords:
Harm reduction; Illicit drug use; Supervised drug consumption facilities; Supervised injection facilities; Systematic review
Authors: Evan Wood; Mark W Tyndall; Ruth Zhang; Jo-Anne Stoltz; Calvin Lai; Julio S G Montaner; Thomas Kerr Journal: N Engl J Med Date: 2006-06-08 Impact factor: 91.245
Authors: Jo-Anne Stoltz; Evan Wood; Will Small; Kathy Li; Mark Tyndall; Julio Montaner; Thomas Kerr Journal: J Public Health (Oxf) Date: 2007-01-17 Impact factor: 2.341
Authors: Evan Wood; Mark W Tyndall; Kathy Li; Elisa Lloyd-Smith; Will Small; Julio S G Montaner; Thomas Kerr Journal: Am J Prev Med Date: 2005-08 Impact factor: 5.043
Authors: Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood Journal: Drug Alcohol Depend Date: 2006-09-07 Impact factor: 4.492
Authors: Abigail K Winiker; Karin E Tobin; Rachel E Gicquelais; Jill Owczarzak; Carl Latkin Journal: Subst Use Misuse Date: 2020-07-09 Impact factor: 2.164
Authors: Kevin Pottie; Claire E Kendall; Tim Aubry; Olivia Magwood; Anne Andermann; Ginetta Salvalaggio; David Ponka; Gary Bloch; Vanessa Brcic; Eric Agbata; Kednapa Thavorn; Terry Hannigan; Andrew Bond; Susan Crouse; Ritika Goel; Esther Shoemaker; Jean Zhuo Jing Wang; Sebastian Mott; Harneel Kaur; Christine Mathew; Syeda Shanza Hashmi; Ammar Saad; Thomas Piggott; Neil Arya; Nicole Kozloff; Michaela Beder; Dale Guenter; Wendy Muckle; Stephen Hwang; Vicky Stergiopoulos; Peter Tugwell Journal: CMAJ Date: 2020-03-09 Impact factor: 8.262
Authors: Kevin Pottie; Claire E Kendall; Tim Aubry; Olivia Magwood; Anne Andermann; Ginetta Salvalaggio; David Ponka; Gary Bloch; Vanessa Brcic; Eric Agbata; Kednapa Thavorn; Terry Hannigan; Andrew Bond; Susan Crouse; Ritika Goel; Esther Shoemaker; Jean Zhuo Jing Wang; Sebastian Mott; Harneel Kaur; Christine Mathew; Syeda Shanza Hashmi; Ammar Saad; Thomas Piggott; Neil Arya; Nicole Kozloff; Michaela Beder; Dale Guenter; Wendy Muckle; Stephen Hwang; Vicky Stergiopoulos; Peter Tugwell Journal: CMAJ Date: 2020-10-13 Impact factor: 8.262
Authors: Mary Clare Kennedy; David C Klassen; Huiru Dong; M-J S Milloy; Kanna Hayashi; Thomas H Kerr Journal: Am J Prev Med Date: 2019-08-01 Impact factor: 5.043
Authors: Jade Boyd; Jennifer Lavalley; Sandra Czechaczek; Samara Mayer; Thomas Kerr; Lisa Maher; Ryan McNeil Journal: Int J Drug Policy Date: 2020-04-02